• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表观遗传因素作为系统性硬化症中纤维化的驱动因素。

Epigenetic factors as drivers of fibrosis in systemic sclerosis.

作者信息

Bergmann Christina, Distler Jörg Hw

机构信息

Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany.

出版信息

Epigenomics. 2017 Apr;9(4):463-477. doi: 10.2217/epi-2016-0150. Epub 2017 Mar 27.

DOI:10.2217/epi-2016-0150
PMID:28343418
Abstract

Prolonged activation of fibroblasts is a central hallmark of fibrosing disorders such as systemic sclerosis (SSc). Fibroblasts are the key effector cells. They differentiate into an activated myofibroblast phenotype. In contrast to normal wound healing with transient activation, myofibroblasts persist in fibrosing disorders. Current hypothesis suggests that profibrotic cytokines might trigger epigenetic changes which contribute to the persistently activated fibroblast phenotype. In the last years, several epigenetic alterations have been described in SSc and have been linked to different pathogenic aspects of the disease, in particular to aberrant fibroblast activation and tissue fibrosis, but also to vascular manifestations and inflammation. The focus of this review is the current knowledge on epigenetic changes in fibroblast activation in SSc.

摘要

成纤维细胞的长期激活是诸如系统性硬化症(SSc)等纤维化疾病的核心特征。成纤维细胞是关键效应细胞。它们分化为活化的肌成纤维细胞表型。与短暂激活的正常伤口愈合不同,肌成纤维细胞在纤维化疾病中持续存在。目前的假说认为,促纤维化细胞因子可能引发表观遗传变化,这些变化促成了成纤维细胞表型的持续激活。在过去几年中,SSc中已描述了几种表观遗传改变,并与该疾病的不同致病方面相关联,特别是与异常的成纤维细胞激活和组织纤维化有关,但也与血管表现和炎症有关。本综述的重点是关于SSc中纤维母细胞活化表观遗传变化的当前知识。

相似文献

1
Epigenetic factors as drivers of fibrosis in systemic sclerosis.表观遗传因素作为系统性硬化症中纤维化的驱动因素。
Epigenomics. 2017 Apr;9(4):463-477. doi: 10.2217/epi-2016-0150. Epub 2017 Mar 27.
2
Epigenetic modulation as a therapy in systemic sclerosis.表观遗传学调控作为系统性硬化症的一种治疗方法。
Rheumatology (Oxford). 2019 Feb 1;58(2):191-196. doi: 10.1093/rheumatology/key071.
3
Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH.长链非编码 RNA HOTAIR 通过 miRNA 34a 依赖性激活 NOTCH 驱动系统性硬化症中 EZH2 依赖性肌成纤维细胞激活。
Ann Rheum Dis. 2020 Apr;79(4):507-517. doi: 10.1136/annrheumdis-2019-216542. Epub 2020 Feb 10.
4
Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis.系统性硬皮病纤维化的细胞和分子发病机制的研究进展。
Transl Res. 2019 Jul;209:77-89. doi: 10.1016/j.trsl.2019.02.010. Epub 2019 Feb 23.
5
Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts.硬皮病成纤维细胞中I型胶原蛋白表达增强与FLI1基因表观遗传抑制之间的关联。
Arthritis Rheum. 2006 Jul;54(7):2271-9. doi: 10.1002/art.21948.
6
TGF-β-induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis.TGF-β 诱导的 SOCS3 表观遗传失调促进 STAT3 信号转导以促进纤维化。
J Clin Invest. 2020 May 1;130(5):2347-2363. doi: 10.1172/JCI122462.
7
Epigenetic mechanisms: An emerging role in pathogenesis and its therapeutic potential in systemic sclerosis.表观遗传机制:在系统性硬化症发病机制中的新作用及其治疗潜力
Int J Biochem Cell Biol. 2015 Oct;67:92-100. doi: 10.1016/j.biocel.2015.05.023. Epub 2015 Jun 1.
8
Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis.自身抗体的致病作用及免疫和结缔组织细胞异常表观遗传调控在系统性硬皮病患者组织纤维化中的作用。
Int J Mol Sci. 2020 Apr 27;21(9):3069. doi: 10.3390/ijms21093069.
9
[Research progress in epigenetic studies on systemic sclerosis].系统性硬化症表观遗传学研究进展
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018 Dec 28;43(12):1369-1375. doi: 10.11817/j.issn.1672-7347.2018.12.014.
10
Epigenetics, the holy grail in the pathogenesis of systemic sclerosis.表观遗传学,系统性硬化症发病机制中的圣杯。
Rheumatology (Oxford). 2015 Oct;54(10):1759-70. doi: 10.1093/rheumatology/keu155. Epub 2014 Apr 16.

引用本文的文献

1
Emerging therapies for the treatment of systemic sclerosis.系统性硬化症的新兴治疗方法。
Nat Rev Rheumatol. 2025 Sep 8. doi: 10.1038/s41584-025-01294-x.
2
Fibrosis: cross-organ biology and pathways to development of innovative drugs.纤维化:跨器官生物学与创新药物研发途径
Nat Rev Drug Discov. 2025 Mar 18. doi: 10.1038/s41573-025-01158-9.
3
Recent Insights into the Role of DNA Methylation and Histone Modifications in Systemic Sclerosis: A Scoping Review.DNA甲基化和组蛋白修饰在系统性硬化症中的作用的最新见解:一项范围综述
Diagnostics (Basel). 2024 Mar 20;14(6):652. doi: 10.3390/diagnostics14060652.
4
An update on epigenetic regulation in autoimmune diseases.自身免疫性疾病中表观遗传调控的最新进展。
J Transl Autoimmun. 2022 Dec 9;5:100176. doi: 10.1016/j.jtauto.2022.100176. eCollection 2022.
5
Metallopeptidades 2 and 9 genes epigenetically modulate equine endometrial fibrosis.金属肽酶2和9基因通过表观遗传调控马子宫内膜纤维化。
Front Vet Sci. 2022 Aug 12;9:970003. doi: 10.3389/fvets.2022.970003. eCollection 2022.
6
Epigenetics of scleroderma: Integrating genetic, ethnic, age, and environmental effects.硬皮病的表观遗传学:整合遗传、种族、年龄和环境因素的影响
J Scleroderma Relat Disord. 2019 Oct;4(3):238-250. doi: 10.1177/2397198319855872. Epub 2019 Jul 3.
7
Therapeutic molecular targets of SSc-ILD.系统性硬化症相关间质性肺疾病的治疗分子靶点。
J Scleroderma Relat Disord. 2020 Mar;5(2 Suppl):17-30. doi: 10.1177/2397198319899013. Epub 2020 Jan 22.
8
The role of TGF-β or BMPR2 signaling pathway-related miRNA in pulmonary arterial hypertension and systemic sclerosis.TGF-β 或 BMPR2 信号通路相关 miRNA 在肺动脉高压和系统性硬化症中的作用。
Arthritis Res Ther. 2021 Nov 25;23(1):288. doi: 10.1186/s13075-021-02678-6.
9
Novel Concepts in Systemic Sclerosis Pathogenesis: Role for miRNAs.系统性硬化症发病机制的新观念:微小RNA的作用
Biomedicines. 2021 Oct 14;9(10):1471. doi: 10.3390/biomedicines9101471.
10
Current Concepts on the Pathogenesis of Systemic Sclerosis.系统性硬化症发病机制的现代概念。
Clin Rev Allergy Immunol. 2023 Jun;64(3):262-283. doi: 10.1007/s12016-021-08889-8. Epub 2021 Sep 6.